Biopharmaceutical firm Altimmune has partnered with the University of Alabama at Birmingham (UAB) to develop a Covid-19 vaccine for intranasal administration.
AdCOVID, the vaccine candidate, will be a single-dose formulation. Altimmune has already created the candidate and is working towards immunogenicity studies.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The company is also preparing to produce Phase I clinical trial material.
